HIV
Conditions
Interventions
DHA combined with ART treatment group (high-dose DHA group):High-dose DHA combined with ART intervention
DHA treatment group (not receiving ART):DHA(Dihydroartemisinin)
Conventional ART treatment group (INRs control group): ART(Antiviral Therapy) intervention
DHA combined with ART treatment group (low-dose DHA group):Low-dose DHA combined with ART intervention
Control group (did not receive ART):None
Sponsors
Beijing Youan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.DHA treatment INRs studies: (1) confirmed experimental diagnosis of HIV infection; (2) Age 18~65 years old; (3) Body weight 50~90 kg; (4) Meet the diagnostic criteria for poor immune reconstitution: continuous ART treatment for more than 2 years; Plasma HIV load less than 50 copies/ml for more than 1 year; CD4 T lymphocyte count less than 350 cells/µL or annual increase of less than 20% from baseline; (5) Good compliance, able to ensure regular follow-up and specimen collection; (6) Volunteer to participate in this study and sign the informed consent form. 2.Study of DHA treatment in HIV-infected individuals not receiving ART: (1) Confirmed laboratory diagnosis of HIV infection; (2) Age 18–65 years; (3) Weight 50–90 kg; (4) After routine ART adherence counseling, the participant temporarily does not receive ART; (5) Good adherence, able to attend regular follow-ups and sample collection; (6) Voluntarily participates in this study and signs the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Presence of other acute or chronic somatic or mental disorders; (2) Poor ART adherence; (3) Use of immunosuppressants or immune modulators within 6 months prior to screening, as well as other medications that may affect this study; (4) Other situations where the investigator believes the participant is unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD4+ T cell count;T cell activation markers (CD38, HLA-DR); | — |
Secondary
| Measure | Time frame |
|---|---|
| HIV DNA reservoir level;Plasma HIV RNA viral load;Expression level of candidate genes;Incidence of adverse events;T cell subset distribution; | — |
Countries
China
Contacts
Public ContactZhang Tong
Beijing Youan Hospital, Capital Medical University
Outcome results
None listed